Research To Practice | Oncology Videos

View Top 200 Chart

Back to Rankings Page

Science
**Research To Practice | Oncology Videos**

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Latest Episodes:

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2 Sep 14, 2026

Show notes

Featuring perspectives from Dr Rachel N Grisham, including the following topics:

Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00)
Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (10:03)
Case: A woman in her late 70s with KRAS-mutated recurrent LGSOC develops congestive heart failure on trametinib and then receives avutometinib/defactinib (16:15)
Case: A woman in her mid 60s with recurrent BRAF V600E LGSOC has concerns about side effects and receives single-agent dabrafenib (19:49)

CME information and select publications

Low-Grade Serous Ovarian Cancer — 5-Minute Journal Club: Microlearning Activity 1 Sep 13, 2026

Show notes

Featuring perspectives from Dr Rachel N Grisham, including the following topics:

Mechanism, clinical evidence and practical use of avutometinib with defactinib for recurrent low-grade serous ovarian cancer (LGSOC) (0:00)
A Phase III trial of letrozole alone as front-line treatment for LGSOC (11:11)
Current and future role of avutometinib with defactinib for LGSOC (19:23)
A Phase II/III trial of trametinib for recurrent LGSOC: Biomarker analyses and clinical implications (21:37)

CME information and select publications

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus Sep 12, 2026

Show notes

Featuring an interview with Prof Andreas Hochhaus, including the following topics:

Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00)
Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09)
Potential mechanisms of adverse events documented with TKIs (10:23)
Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23)
Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14)
Comparative efficacy of asciminib and other agents used to treat CML (40:01)
Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53)
Practical care strategies for CML patients; future developments (52:32)

CME information and select publications

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture) Sep 11, 2026

Show notes

Featuring a slide presentation and related discussion from Prof Andreas Hochhaus, including the following topics:

· Historical evolution of the treatment landscape for chronic myeloid leukemia and goals of clinical care (0:00)

· Current therapeutic landscape and available long-term data (10:22)

· Mechanism of action of asciminib and key findings from the ASC4FIRST study (16:50)

· Key clinical trial data from the ASC4START study and factors in treatment selection (23:15)

· Investigational therapies and ongoing clinical trials (27:51)

CME information and select publications

Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer Sep 11, 2026

Show notes

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:

Case: A woman in her late 60s with recurrence of metastatic estrogen receptor-positive endometrial cancer enrolls in a trial of CDK4/6 inhibition with an aromatase inhibitor 1 year into maintenance dostarlimab after carboplatin/paclitaxel/dostarlimab and has no evidence of disease 3 years later (0:00)
Adding a PARP inhibitor to immunotherapy and chemotherapy: The RUBY Part 2 and DUO-E trials (10:03)

CME information and select publications

Non-Small Cell Lung Cancer — Targeting KRAS G12C Sep 10, 2026

Show notes

Featuring perspectives from Prof Solange Peters and Dr Joshua K Sabari, including the following topics:

Introduction (0:00)
Best Option for Your Patient (1:28)
Biological Considerations (6:26)
KRAS G12C Inhibitors (11:33)
Second-Line Treatment (13:02)
Current Clinical Trials in the First-Line Metastatic Setting (32:18)
Current Clinical Trials in the Localized Setting (49:52)
Current Clinical Trials with New Treatment Combinations and Agents (53:51)

CME information and select publications

Prostate Cancer — The Optimal Use of Hormonal Therapy Sep 08, 2026

Show notes

Featuring perspectives from Dr William K Oh and Dr Mary-Ellen Taplin, including the following topics:

Introduction: Another Perspective on the Treatment of Localized Prostate Cancer (0:00)
Nonmetastatic Disease (10:32)
Metastatic Androgen Pathway Modulation-Naïve and Androgen Pathway Modulation-Sensitive Disease (41:50)

CME information and select publications

Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 4 Sep 07, 2026

Show notes

Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:

Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00)
Case: A man in his late 60s with bulky CLL diagnosed abroad receives zanubrutinib monotherapy (12:48)
Case: A man in his late 40s with IGHV-mutated, del(13q) CLL with worsening symptoms and diffuse adenopathy after 1 year of observation receives venetoclax/obinutuzumab and attains a complete response (21:29)

CME information and select publications

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3 Sep 06, 2026

Show notes

Featuring perspectives from Prof John Seymour, including the following topics:

Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)
Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21)
First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10)

CME information and select publications

AKT Inhibition in Prostate Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium Sep 05, 2026

Show notes

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:

Tolerability of capivasertib and management of associated side effects — Question from Neeraj Agarwal, MD, FASCO (0:00)
Case: A man in his early 70s with Type 2 diabetes presents with metastatic hormone-sensitive prostate cancer with widespread bone metastases and PTEN deficiency on next-generation sequencing and receives relugolix/darolutamide — Rana R McKay, MD, FASCO (8:39)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected